CPRX
Catalyst Pharmaceuticals Inc
NASDAQ: CPRX · HEALTHCARE · BIOTECHNOLOGY
$31.40
+0.06% today
Updated 2026-06-23
Market cap
$3.84B
P/E ratio
18.13
P/S ratio
6.43x
EPS (TTM)
$1.73
Dividend yield
—
52W range
$19 – $33
Volume
2.3M
WallStSmart proprietary scores
62
out of 100
Grade: C+
Hold
Investment rating
7.3
Growth
B+8.5
Quality
A9.5
Profitability
A+5.3
Valuation
C+3/9
Piotroski F-Score
Weak
6.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$32.17
+2.45%
12-Month target
$21.59
-31.24%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy5 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 6.54 — safe zone
+ Profit margin 37.10% — above average
+ ROE 21.85% — strong efficiency
+ Free cash flow $59.56M — positive
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $214.20M | $398.20M | $491.73M | $588.99M | $596.96M | $0.6B |
| Net income | $83.08M | $71.41M | $163.89M | $214.33M | $63.73M | — |
| EPS | — | — | — | — | $1.73 | $2.06 |
| Free cash flow | $116.02M | $61.86M | $239.25M | $208.61M | $59.56M | — |
| Profit margin | 38.79% | 17.93% | 33.33% | 36.39% | 37.10% | — |
Peer comparison
Smart narrative
Catalyst Pharmaceuticals Inc trades at $31.40. representing a P/E of 18.13x trailing earnings. Our Smart Value Score of 62/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 6.54, it sits in the safe zone. TTM revenue stands at $596.96M. with profit margins at 37.10%.
Frequently asked questions
What is Catalyst Pharmaceuticals Inc's stock price?
Catalyst Pharmaceuticals Inc (CPRX) trades at $31.40, on a P/E of 18.1x and a P/S of 6.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Catalyst Pharmaceuticals Inc overvalued?
Catalyst Pharmaceuticals Inc carries a Smart Value Score of 62/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Catalyst Pharmaceuticals Inc (CPRX)?
The 12-month analyst consensus target is $32.17, about 2.5% above the current $31.40. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of CPRX by 2030?
Our research-backed model puts the 2030 base case at $34.70, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Catalyst Pharmaceuticals Inc's revenue?
Catalyst Pharmaceuticals Inc's trailing twelve-month revenue is $596.96M, and our model projects it reaching about $954.62M by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Catalyst Pharmaceuticals Inc's Altman Z-Score is 6.54, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.43x
ROE21.85%
Beta0.74
50D MA$29.19
200D MA$24.21
Shares out0.12B
Float0.12B
Short ratio—
Avg volume2.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—